Table 1.
Patient characteristics by treatment group (Cohort 1)
| |
ICI Treatment Group |
||
|---|---|---|---|
| Characteristics | Anti-CTLA4 (n = 23) |
Anti-PD1 (n = 48) |
Anti-CTLA4 plus Anti-PD1 (n = 42) |
| Age [years] | |||
| Median (range) | 59 (30–86) | 70 (37–90) | 56 (22–77) |
| n (%) | n (%) | n (%) | |
| Sex | |||
| Male | 16 (70) | 31 (65) | 21 (50) |
| Female | 7 (30) | 17 (35) | 21 (50) |
| Braf Status | |||
| Mutation | 11 (48) | 16 (33) | 18 (43) |
| Wild Type | 11 (48) | 30 (63) | 19 (45) |
| Missing | 1 (4) | 2 (4) | 5 (12) |
| Serum LDH | |||
| Elevated | 11 (48) | 13 (27) | 18 (43) |
| Normal | 10 (43) | 35 (73) | 24 (57) |
| Missing | 2 (9) | ||
| Prior Systemic Treatment | |||
| No | 12 (52) | 21 (44) | 23 (55) |
| Yes* | 11 (48) | 27 (56) | 19 (45) |
| Tumor Stage | |||
| M0, M1a, M1b | 9 (39) | 15 (31) | 13 (31) |
| M1c, M1d | 14 (61) | 33 (69) | 29 (69) |
| Liver Metastases | |||
| Yes | 4 (17) | 8 (17) | 17 (40) |
| No | 19 (83) | 40 (83) | 25 (60) |
| Brain Metastases | |||
| Yes | 8 (35) | 21 (44) | 14 (33) |
| No | 15 (65) | 27 (56) | 28 (67) |
| Response | |||
| CR | 0 (0) | 2 (4) | 3 (7) |
| PR | 5 (22) | 12 (25) | 13 (31) |
| SD | 5 (22) | 14 (29) | 10 (24) |
| PD | 13 (56) | 20 (42) | 16 (38) |
| RR (PR+CR) | 5 (22) | 14 (29) | 16 (38) |
| DCR (SD+PR+CR) | 10 (44) | 28 (58) | 26 (62) |
| PFS [months] | |||
| Median (range) | 3 (0–37) | 7 (1–56) | 6 (1–35) |
| Follow up [months] | |||
| Median (range) | 15 (4–90) | 15 (3–56) | 13,5 (3–37) |
*Prior Systemic therapy was mainly chemotherapy for the anti-CTLA4 group, anti-CTLA4 for the anti-PD1 group, and anti-PD1 for the anti-CTLA4 plus anti-PD1 group.